Phase 2 N=48 A Phase II Study of Neoadjuvant FOLFIRINOX
Resectable Pancreatic Ductal Adenocarcinoma
Primary: Percentage of Patients With Pathologic Complete Response — 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 GRX With ReMOTE: First in Human in India
Percutaneous Coronary Intervention
Primary: Device Technical Success — 5 Participants
Phase 3 N=98 A Phase 3 Clinical Study Investigating the Gingivitis Efficacy of a Test Dentifrice Containing Stannous Fluoride
Gingivitis
Primary: Evaluation and Comparison of Gingival Health Measured by Bleeding Index (BI) at 24 Weeks — 0.11; 0.19 Score on scale — p=<0.0001
Phase 2 N=291 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia
Chronic Insomnia · Adults · Elderly
Primary: Probability of Having Utility Function Greater Than (>) 1 Based on Bayesian Analysis — 0.8789; 0.8920; 0.9032; 0.9406 probability
Phase 1 N=56 A Study of Lasmiditan on the Heart in Healthy Participants
Healthy
Primary: Change From Time Matched Baseline in Mean Fridericia-Corrected QT (QTcF) Values of Lasmiditan and Moxifloxacin — -8.90; -9.27; -5.49; 1.90 milliseconds
Phase 3 N=247 Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
Post Ocular Surgical Inflammation and Pain
Primary: Absence of Cells in Anterior Chamber of the Study Eye — 54; 12 Participants
Phase 4 N=23 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)
Hypogonadism · Severe Obesity
Primary: Percent Change in Muscle Strength as Assessed by Knee Extension and Knee Flexion — 12.6; 8.9; 12.8; 3.7 Percent change in muscle strength
N/A N=311 A Mobile Personal Health Record for Behavioral Health Homes
Hypertension · Hyperlipidemia · Diabetes
Primary: Change in Composite Quality Score — 0.71; 0.70; 0.67; 0.70 score on a scale
Phase 4 N=70 Pilot - Peri-operative Beta Blockade
Adrenergic Beta-Receptor Blockader · Troponin Levels · Cardiomyopathy, Post-surgical
Primary: Difference in hscTnI Values — 3.4; 2.8 ng/L
N/A N=219 Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)
Leber's Hereditary Optic Neuropathy (LHON)
Primary: In Eyes With VA Assessment Made ≤1 Year After Onset of Symptoms: Proportion of Eyes With Clinically Relevant Recovery (CRR) of VA (Measured by Change in ETDRS Letters)…
Phase 2 N=8 Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Epidermolysis Bullosa Simplex · Epidermolysis Bullosa Simplex Kobner · Weber-Cockayne Syndrome
Primary: Foot Health Status Questionnaire, Foot Function Domain Score — 61.7; 49.3; 60.2; 56.3 score on a scale
Phase 2 N=24 Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
Leukemia, Lymphocytic, Chronic, B-Cell · Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Incidence and Severity of Adverse Events (AEs) — 11; 13 Participants
Phase 4 N=31 Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA
Diabetic Macular Edema · Ischemic Maculopathy
Primary: FAZ Area Change — 0.03 mm^2
Phase 3 N=30 Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections
Refractory Bone or Joint Infections
Primary: Clinical Success at 6 Months — 18; 9; 3 Participants
N/A N=86 Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment
Primary Open-angle Glaucoma
Primary: Completion of Selective Laser Trabeculoplasty (SLT) — 10; 6 Participants